Zevra Therapeutics, Inc.

ZVRA Healthcare Biotechnology

Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024. In the quarter to June 2026, revenue grew 53.3%, EPS fell 88.7%, free cash flow grew 670.9% and total debt rose 4.07%, each against the same quarter a year earlier.

9.95 0.32 −3.12%
Market cap
$609.9M
P/E
10.5×
Fwd P/E
10.5×
Dividend yield
—
F-score
6/9
Altman Z
0.63
Beneish M
1.46
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Total current assets
223.01 86.03 86.94 92.83 115.06 8.38 6.97 23.72 45.90 74.36
Total non-current assets
61.72 92.10 85.39 22.51 17.89 2.83 3.54 3.03 6.56 10.53
Total Assets
284.73 178.13 172.33 115.34 132.94 11.21 10.51 26.75 52.46 84.89
Total current liabilities
39.28 34.07 73.72 12.02 4.23 7.54 5.43 12.00 11.51 6.64
Total non-current liabilities
90.80 104.40 36.74 28.20 1.59 70.09 79.53 81.31 98.46 96.94
Total liabilities
130.07 138.46 110.46 40.22 5.82 77.62 84.96 93.31 109.97 103.58
Common Equity (Total)
154.66 39.67 61.86 75.12 127.12 (66.41) (74.46) (66.57) (57.52) (18.70)
Shareholders Equity (Total)
154.66 39.67 61.86 75.12 127.12 (66.41) (74.46) (66.57) (57.52) (18.70)
Total Debt
61.93 59.50 42.77 13.29 1.61 68.44 77.86 82.05 93.48 91.98

Show all line items

In millions of $ except per-share values · columns are period end dates